Last reviewed · How we verify
NCT02968953
Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome
trial testing Triheptanoin in Glucose Transporter 1 Deficiency Syndrome. No longer available.
Quick facts
| Lead sponsor | Jerry Vockley, MD, PhD |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- Triheptanoin — full drug profile →
Conditions studied
- Glucose Transporter 1 Deficiency Syndrome — all drugs for Glucose Transporter 1 Deficiency Syndrome →
Sponsor
Jerry Vockley, MD, PhD
Who can join
3 and older, female only, with Glucose Transporter 1 Deficiency Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02968953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Triheptanoin
Trials testing the same drug.
- NCT06340685 — Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency · Phase 1 · recruiting
- NCT04513002 — Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis · Phase 2 · completed
- NCT03665636 — Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I · EARLY_PHASE1 · completed
- NCT03642860 — The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses · Phase 2 · completed
- NCT03506425 — A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) · Phase 1, PHASE2 · completed
Other Jerry Vockley, MD, PhD trials
Trials by the same sponsor.
- NCT01461304 — Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism · no longer available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02968953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jerry Vockley, MD, PhD
- Last refreshed: 8 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02968953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing